循環器ジャーナル66巻1号

2018年01月発行

特集 循環器診療　薬のギモン—エキスパートに学ぶ薬物治療のテクニック Ⅳ．不整脈診療でのギモン

AFに対する抗不整脈薬，抗コリン薬は，どういう人に使ったらいいの？アミオダロンはどういうときに使うの？

著者： 萩原かな子¹ 岩崎雄樹¹ 清水渉¹

所属機関： ¹日本医科大学付属病院循環器内科

ページ範囲：P.108 - P.114

Point
・心房細動の治療方針はそれぞれの患者の基礎疾患や臨床背景を十分考慮したうえで決定する．
・抗不整脈薬による治療は決して無理をせず一つの方針に固執しないことが大切である．

参考文献

1) Hohnloser SH, Kuck KH, Lilienthal J:Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation（PIAF）:a randomised trial. Lancet 356:1789-1794, 2000

2) Van Gelder IC, Hagens VE, Bosker HA, et al:A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834-1840, 2002

3) Wyse DG, Waldo AL, DiMarco JP, et al:A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002

4) Saksena S, Slee A, Waldo AL, et al:Cardiovascular outcomes in the AFFIRM Trial（Atrial Fibrillation Follow-Up Investigation of Rhythm Management）. An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol 58:1975-1985, 2011

5) Ogawa S, Yamashita T, Yamazaki T, et al:Optimal treatment strategy for patients with paroxysmal atrial fibrillation:J-RHYTHM Study. Circ J 73:242-248, 2009

6) Gupta S, Figueredo VM:Tachycardia mediated cardiomyopathy:pathophysiology, mechanisms, clinical features and management. Int J Cardiol 172:40-46, 2014

7) Horiuchi D, Iwasa A, Sasaki K, et al:Effect of pilsicainide on dominant frequency in the right and left atria and pulmonary veins during atrial fibrillation:association with its atrial fibrillation terminating effect. Eur J Pharmacol 608:54-61, 2009

8) Kanki H, Mitamura H, Takatsuki S, et al:Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. Cardiovasc Drugs Ther 12:475-482, 1998

9) Fukuda K, Watanabe J, Yagi T, et al:A sodium channel blocker, pilsicainide, produces atrial post-repolarization refractoriness through the reduction of sodium channel availability. Tohoku J Exp Med 225:35-42, 2011

10) Hoekstra BP, Diks CG, Allessie MA, DeGoede J:Spatial correlation analysis of the pharmacological conversion of sustained atrial fibrillation in conscious goats by cibenzoline. Arch Physiol Biochem 108:332-348, 2000

11) Kawase A, Ikeda T, Nakazawa K, et al:Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria. Circulation 107:905-910, 2003

12) Kumagai K, Tojo H, Noguchi H, et al:Effects of the NA＋ channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation. J Cardiovasc Electrophysiol 15:1396-1401, 2004

13) Atarashi H, Inoue H, Hiejima K, Hayakawa H:Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide（Pilsicainide Suppression Trial on atrial fibrillation）. The PSTAF Investigators. Am J Cardiol 78:694-697, 1996

14) 戸叶隆司，中里祐二，土屋洋人，他：発作性および持続性心房細動に対するシベンゾリン経口単回投与による薬理学的除細動に関する検討．心電図29:50-57, 2009

15) Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, et al:Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 86:950-953, 2000

16) Hsu JC, Chan PS, Tang F, et al:Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation. Am J Med 128:654.e1-654.e10, 2015

17) 小松　隆，中村　紳，蓬田邦彦：発症時間帯からみた発作性心房細動に対するdisopyramideの停止効果・長期予防効果．心臓33:29-35, 2001

18) Reisinger J, Gatterer E, Heinze G, et al:Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 81:1450-1454, 1998

19) Singh BN, Singh SN, Reda DJ, et al:Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352:1861-1872, 2005

20) Yamashita T, Ogawa S, Sato T, et al:Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms:a multicenter, randomized, placebo-controlled, double-blind study（J-BAF Study）. Circ J 73:1020-1027, 2009

21) Humphries KH, Kerr CR, Connolly SJ, et al:New-onset atrial fibrillation:sex differences in presentation, treatment, and outcome. Circulation 103:2365-2370, 2001